These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

490 related items for PubMed ID: 22212248

  • 1. A randomized comparison of two prophylaxis regimens and a paired comparison of on-demand and prophylaxis treatments in hemophilia A management.
    Valentino LA, Mamonov V, Hellmann A, Quon DV, Chybicka A, Schroth P, Patrone L, Wong WY, Prophylaxis Study Group.
    J Thromb Haemost; 2012 Mar; 10(3):359-67. PubMed ID: 22212248
    [Abstract] [Full Text] [Related]

  • 2. Phase 4 Safety and Efficacy Study of Antihemophilic Factor (Recombinant) in Previously Treated Chinese Patients With Severe/Moderately Severe Hemophilia A.
    Zhao Y, Hu Y, Jin J, Zhao X, Wang X, Wu R, Wu D, Yang R, Yang F, Hu Q, Wang J, Fang H, Engl W.
    Clin Appl Thromb Hemost; 2021 Mar; 27():1076029621989811. PubMed ID: 33587652
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Clinical evaluation of glycoPEGylated recombinant FVIII: Efficacy and safety in severe haemophilia A.
    Giangrande P, Andreeva T, Chowdary P, Ehrenforth S, Hanabusa H, Leebeek FW, Lentz SR, Nemes L, Poulsen LH, Santagostino E, You CW, Clausen WH, Jönsson PG, Oldenburg J, Pathfinder™2 Investigators.
    Thromb Haemost; 2017 Jan 26; 117(2):252-261. PubMed ID: 27904904
    [Abstract] [Full Text] [Related]

  • 5. Factor VIII requirement to maintain a target plasma level in the prophylactic treatment of severe hemophilia A: influences of variance in pharmacokinetics and treatment regimens.
    Collins PW, Björkman S, Fischer K, Blanchette V, Oh M, Schroth P, Fritsch S, Casey K, Spotts G, Ewenstein BM.
    J Thromb Haemost; 2010 Feb 26; 8(2):269-75. PubMed ID: 19943875
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Efficacy and safety of secondary prophylactic vs. on-demand sucrose-formulated recombinant factor VIII treatment in adults with severe hemophilia A: results from a 13-month crossover study.
    Collins P, Faradji A, Morfini M, Enriquez MM, Schwartz L.
    J Thromb Haemost; 2010 Jan 26; 8(1):83-9. PubMed ID: 19817995
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Decreased Bleeding Rates in Patients with Hemophilia A Switching from Standard-Half-Life FVIII to BAY 94-9027 Prophylaxis.
    Mancuso ME, Reding MT, Negrier C, Kerlin BA, Rangarajan S, Simpson ML.
    Thromb Haemost; 2021 Aug 26; 121(8):1079-1086. PubMed ID: 33296943
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. A Retrospective Observational Study of Rurioctocog Alfa Pegol in Clinical Practice in the United States.
    Aledort L, Milligan S, Watt M, Booth J.
    J Manag Care Spec Pharm; 2020 Apr 26; 26(4):492-503. PubMed ID: 32223610
    [Abstract] [Full Text] [Related]

  • 12. Plasma and albumin-free recombinant factor VIII: pharmacokinetics, efficacy and safety in previously treated pediatric patients.
    Blanchette VS, Shapiro AD, Liesner RJ, Hernández Navarro F, Warrier I, Schroth PC, Spotts G, Ewenstein BM, rAHF-PFM Clinical Study Group.
    J Thromb Haemost; 2008 Aug 26; 6(8):1319-26. PubMed ID: 18503631
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Octocog alfa (Advate®): a guide to its use in hemophilia A.
    Keating GM, Dhillon S.
    BioDrugs; 2012 Aug 01; 26(4):269-73. PubMed ID: 22759264
    [Abstract] [Full Text] [Related]

  • 16. A Real-World Analysis of Commonly Prescribed FVIII Products Based on U.S. Medical Charts: Consumption and Bleeding Outcomes in Hemophilia A Patients.
    Yan S, Maro GS, Desai V, Simpson ML.
    J Manag Care Spec Pharm; 2020 Oct 01; 26(10):1258-1265. PubMed ID: 32820685
    [Abstract] [Full Text] [Related]

  • 17. Perioperative treatment of hemophilia A patients: blood group O patients are at risk of bleeding complications.
    Hazendonk HC, Lock J, Mathôt RA, Meijer K, Peters M, Laros-van Gorkom BA, van der Meer FJ, Driessens MH, Leebeek FW, Fijnvandraat K, Cnossen MH.
    J Thromb Haemost; 2016 Mar 01; 14(3):468-78. PubMed ID: 26714028
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Association of peak factor VIII levels and area under the curve with bleeding in patients with haemophilia A on every third day pharmacokinetic-guided prophylaxis.
    Valentino LA, Pipe SW, Collins PW, Blanchette VS, Berntorp E, Fischer K, Ewenstein BM, Oh M, Spotts G.
    Haemophilia; 2016 Jul 01; 22(4):514-20. PubMed ID: 26930418
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 25.